Rockwell Medical (STU:RWM) Moat Score: 4/10 (As of Jul. 05, 2026)


STU:RWM Rockwell Medical Inc STU:RWM
26 GF Score
Price €4.80
GF Value €0.82
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Rockwell Medical Moat Score?

Rockwell Medical STU:RWM 26 Moat Score is 4 as of Jul. 05, 2026. GuruFocus rates STU:RWM with a GF Score™ of 26/100 and a GF Value™ of €0.82 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Rockwell Medical ranks better than 90.68% on this metric.

Rockwell Medical has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Rockwell Medical has Narrow Moat: Rockwell Medical Inc has some proprietary technology and regulatory approvals in the medical field, providing modest competitive advantages. However, it faces significant competition and lacks strong brand loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Rockwell Medical might have Narrow Moat - Discernible but modest moat.

Rockwell Medical  (STU:RWM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Rockwell Medical Moat Score Related Terms

STU:RWM vs CPHI, TXMD, MRMD: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rockwell Medical Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Moat Score distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's Moat Score falls into.


STU:RWM
26GF Score
Rockwell Medical Inc STU:RWM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Rockwell Medical (STU:RWM) has a Moat Score of 4 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Rockwell Medical ranks #96 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Rockwell Medical's Moat Score too high?
Rockwell Medical's current Moat Score is 4. Based on the distribution chart, Rockwell Medical ranks #96 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rockwell Medical has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Moat Score compare to CPHI and TXMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #96 out of 1030 companies for Moat Score. This places Rockwell Medical in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Rockwell Medical's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (STU:RWM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.82, compared to a current price of €4.80 — trading 485.4% above its estimated fair value. The current Moat Score is 4. Rockwell Medical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Rockwell Medical (STU:RWM), the current Moat Score is 4 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (STU:RWM) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued. The current stock price of €4.80 is trading 485.4% above its estimated GF Value™ of €0.82. GuruFocus considers Rockwell Medical to be Significantly Overvalued.

Key valuation signals for STU:RWM:

  • Moat Score: 4
  • GF Value™: €0.82 vs. price of €4.80 (485.4% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the STU:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rockwell Medical Business Description

Other Exchanges RMTI:USARWMA:Germany
Address 30142 South Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
26GF Score

Get the complete analysis for STU:RWM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.80
Price
€0.82
GF Value